| Ident. | Authors (with country if any) | Title |
|---|
| 002840 (2013) |
Mark C. Genovese [États-Unis] ; Roy M. Fleischmann [États-Unis] ; Maria Greenwald [États-Unis] ; Julie Satterwhite [États-Unis] ; Melissa Veenhuizen [États-Unis] ; Li Xie [États-Unis] ; Pierre-Yves Berclaz [États-Unis] ; Stephen Myers [États-Unis] ; Olivier Benichou [États-Unis] | Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors |
| 002853 (2013) |
Maarten Boers [Pays-Bas] ; Lilian Van Tuyl [Pays-Bas] ; Marianne Van Den Broek [Pays-Bas] ; Piet J. Kostense [Pays-Bas] ; Cornelia F. Allaart [Pays-Bas] | Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis |
| 002854 (2013) |
Carrie L. Wagner [États-Unis] ; Sudha Visvanathan [États-Unis] ; Michael Elashoff [États-Unis] ; Iain B. Mcinnes [Royaume-Uni] ; Philip J. Mease [États-Unis] ; Gerald G. Krueger [États-Unis] ; Frederick T. Murphy [États-Unis] ; Kim Papp [Canada] ; Juan J. Gomez-Reino [Espagne] ; Michael Mack [États-Unis] ; Anna Beutler [Canada] ; Dafna Gladman [Canada] ; Arthur Kavanaugh [États-Unis] | Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab |
| 002864 (2013) |
Philip G. Conaghan [Royaume-Uni] ; Patrick Durez [Belgique] ; Rieke E. Alten [Allemagne] ; Gerd-Rüdiger Burmester [Allemagne] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Lars Klareskog [Suède] ; Anca Irinel Catrina [Suède] ; Julie Dicarlo [États-Unis] ; Corine Gaillez [France] ; Manuela Le Bars [France] ; Xianhuang Zhou [États-Unis] ; Charles Peterfy [États-Unis] | Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial |
| 002867 (2013) |
Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis] | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks |
| 002874 (2013) |
Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| 002881 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas] | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| 002A08 (2013) |
I. Guseva ; N. Demidova ; N. Soroka [Russie] ; E. Panasyuk ; E. Luchikhina ; E. Fedorenko ; E. Alexandrova ; A. Novikov ; D. Trofimov [Russie] ; D. Karateev ; E. Nasonov | THU0164 Polymorphism of Cytotoxic T-Lymphocyte Antigen 4 +49A/G is Associated with Refractoriness to Non-Biological Dmards in Rheumatoid Arthritis Patients |
| 002A09 (2013) |
I. Ancuta ; C. Codreanu ; R. Ionescu ; M. Parvu [Roumanie] ; M. Bojinca | THU0163 Disease Flares Predict the Change to Second Line Therapy in Rheumatoid Arthritis: 9-Year Data from a Longitudinal Observational Study |
| 002A10 (2013) |
I. Ancuta ; C. Codreanu ; R. Ionescu ; M. Parvu [Roumanie] ; M. Bojinca | THU0162 Patterns of Clinical Response Predict Failure of TNF Inhibitor Treatment in Rheumatoid Arthritis: Data from a Longitudinal Observational Study in Romania |
| 002B47 (2013) |
Y. Saeki ; S. Ohshima ; M. Matsushita ; E. Tanaka-Kudo ; S. Tsuji ; M. Yoshimura ; A. Watanabe ; M. Katayama ; S. Teshigawara ; Y. Katada ; Y. Harada ; A. Yura ; K. Kagawa ; J. Hashimoto ; S. Tohma [Japon] | SAT0144 The Causes of Discontinuation of Biologics(Bio)-Use in the Treatment of Rheumatoid Arthritis (RA) Under Practical Circumstances in Japan: from the “Ninja” Registry |
| 002B48 (2013) |
Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | SAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification |
| 002B49 (2013) |
U. Klein [Suisse] ; E. Liang [Suisse] ; B. Vogel [Suisse] ; F. Kolbinger [Suisse] ; G. Bruin [Suisse] ; P. Lloyd [Suisse] | SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients |
| 002B50 (2013) |
T. Kasama [Japon] ; M. Umemura [Japon] ; S. Isojima [Japon] ; T. Tokunaga [Japon] ; H. Tsukamoto [Japon] ; R. Yanai [Japon] ; H. Furuya [Japon] ; Y. Miwa [Japon] | SAT0141 Correlation of Serum Macrophage Migration Inhibitory Factor Levels With Response to Tocilizumab Therapy in Patients with Rheumatoid Arthritis |
| 002B52 (2013) |
T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; M. Hanabayashi [Japon] ; N. Asai [Japon] ; N. Ishiguro [Japon] | SAT0139 Importance of Concomitant MTX Use During Treatment with Tocilizumab in Patients with Rheumatoid Arthritis |
| 002B55 (2013) |
R. Fleischmann [États-Unis] ; S. Fiore ; C. Fan ; D. Thompson [États-Unis] | SAT0136 Sarilumab, a Fully Human Mab Against IL-6R Alpha, Subcutaneously-Administered Shows Significant Improvement in Ra Patients as Early as 2 Weeks: A Time to Event Analysis for Acr50 and Eular Good Response |
| 002C33 (2013) |
Alessandra Blaizot [France] ; Paul Monsarrat [France] ; Arnaud Constantin [France] ; Jean-Noel Vergnes [France] ; Gabriel Fernandez De Grado [France] ; Cathy Nabet [France] ; Alain Cantagrel [France] ; Michel Sixou [France] | Oral health‐related quality of life among outpatients with rheumatoid arthritis |
| 002E98 (2013) |
Z. Ye [République populaire de Chine] ; Z. Yin [République populaire de Chine] ; J. Huang [République populaire de Chine] ; H. Sun [République populaire de Chine] ; X. Luo [République populaire de Chine] | FRI0098 The expression of plasma MIR-155 and MIR-146A in RA patients |
| 002F01 (2013) |
V. Rantalaiho ; H. Kautiainen ; M. Korpela ; S. J Rvenp [Finlande] ; M. Leirisalo-Repo | FRI0092 Disease activity at three months is an excellent predictor of long-term treatment failure in actively treated rheumatoid arthritis patients, 5-year results of the neo-raco trial |
| 002F65 (2013) |
| ARA Scientific Posters |
| 003185 (2013) |
Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | AB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration |
